- Home
- LOMA vs IMTX Comparison
LOMA vs IMTX Comparison
Compare LOMA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOMA | IMTX |
|---|---|---|
| Founded | 1926 | N/A |
| Country | Argentina | Germany |
| Employees | N/A | 407 |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | LOMA | IMTX |
|---|---|---|
| Price | $12.67 | $9.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $15.00 | ★ $19.00 |
| AVG Volume (30 Days) | 467.2K | ★ 586.6K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.53 | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | $187.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.04 | $5.05 |
| 52 Week High | $13.20 | $12.41 |
Technical Indicators
Market Signals| Indicator | LOMA | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.98 | 32.36 |
| Support Level | $11.66 | $5.67 |
| Resistance Level | $13.17 | $10.80 |
| Average True Range (ATR) | 0.56 | 0.61 |
| MACD | 0.06 | -0.24 |
| Stochastic Oscillator | 97.83 | 9.68 |
Price Performance
Historical ComparisonAbout LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.